Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

TCMD 10.02.2024

Full Press ReleaseSEC FilingsOur TCMD Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Tactile Medical Appoints Laura King to Board of Directors
  • 12.18.2024 - Essential Lymphedema Precautions: Managing Symptoms Effectively
  • 12.18.2024 - Age and Lymphedema: What Age Does Lymphedema Occur?

Recent Filings

  • 01.14.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema

MINNEAPOLIS,Oct. 02, 2024(GLOBE NEWSWIRE) --Tactile Systems Technology, Inc.(“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughoutthe United Statesfor the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl receivedU.S Food & Drug Administration(FDA) 510(k) clearance inJune 2024and Pricing, Data Analysis, and Coding (PDAC) approval from theCenters for Medicare & Medicaid Services(CMS) inSeptember 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months.

“We are excited to announce the commercial launch of Nimbl, an important addition to our leading portfolio of patient-focused, clinically proven lymphedema therapy solutions,” saidSheri Dodd, Chief Executive Officer atTactile Medical. “This first phase of Nimbl’s introduction, targeted specifically for upper extremity treatment, is well-timed as we recognize Breast Cancer Awareness Month and the many thousands of patients in need of better treatment solutions. Up to 40% of breast cancer survivors are affected by lifelong, debilitating lymphedema symptoms through swelling and discomfort in the breast, trunk, arms, and hands, and we are proud to provide a highly effective and convenient treatment option. We look forward to expanding Nimbl’s launch to include patients with lower extremity conditions, and we remain committed to advancing solutions that increase patient access to therapy with a differentiated user experience.”

Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company’s current generation basic pneumatic compression device (PCD). Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company’s free KyleeTM digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag.

“Patients and clinicians alike will appreciate the introduction of Nimbl as a compelling treatment option designed to increase adherence and improve clinical outcomes”, saidTony Gasparis, MD, Chief Medical Officer atTactile Medical. “Patients can now more easily fit therapy into their daily routine resulting in long-term relief and increased confidence for clinicians.”

AboutTactile Systems Technology, Inc.(DBA Tactile Medical)

Tactile Medicalis a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home.Tactile Medicalcollaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:Sam BentzingerGilmartin Group[email protected]

Primary Logo

Source: Tactile Systems Technology, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com